Cypress, Organon ending mirtazapine program

CYPB said Phase IIa results do not warrant continuing development of mirtazapine as combination therapy for obstructive sleep apnea because they did not replicate the findings in an earlier study. In a previous investigator-sponsored "pilot" trial, mirtazapine reduced the number of abnormal respiratory events during the night by about 50%. CYPB and Organon had completed independent Phase IIa trials of the antidepressant in combination with an undisclosed approved drug. ...